-
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
Monday, June 28, 2021 - 12:50pm | 386Mind Medicine (MindMed) Inc (NASDAQ: MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock. The Analyst: Maxim analyst Jason McCarthy initiated coverage of MindMed with a Buy rating and $6 price target. The Thesis: McCarthy...
-
Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals
Thursday, May 13, 2021 - 5:13pm | 619At the Benzinga Global Small Cap Conference Thursday, Jason McCarthy, senior managing director at Maxim Group, hosted a panel discussion on how biotech companies are getting back to fundamentals following an extremely disruptive period during the COVID-19 pandemic. The panel discussion included...
-
Maxim Group Upgrades Titan Pharma As 'ProNeura Pivots To Pruritus'
Thursday, February 18, 2021 - 1:06pm | 238Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is set to begin a new phase, according to Maxim Group, after undergoing several changes in strategy, management, capital structure and financing through 2020 and into 2021. The Titan Pharmaceuticals Analyst: Jason McCarthy upgraded the...
-
Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal
Saturday, June 2, 2018 - 4:10pm | 397Viking Therapeutics Inc (NASDAQ: VKTX) shares more than doubled Thursday after a 145-percent jump in shares of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), which announced data from a Phase 2 study of its non-alcoholic steatohepatitis pipeline candidate. NASH is a form of non-alcoholic...
-
Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim
Thursday, March 22, 2018 - 3:42pm | 351Extended Medicare reimbursement for Omeros Corporation (NASDAQ: OMER)’s OMIDRIA, along with the company’s increased focus on OMS721 trials, will act as solid short- and long-term drivers, according to Maxim Group. The Analyst Jason McCarthy of Maxim Group maintained a Buy rating...
-
Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade
Thursday, March 15, 2018 - 1:12pm | 331Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver disease. However, the drug is now generating optimism for distinct indications. The Analyst Maxim Group analyst Jason McCarthy upgraded Galmed to Buy and...
-
Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher
Wednesday, December 13, 2017 - 11:24am | 422Bluebird bio Inc (NASDAQ: BLUE)'s stock has soared more than 200 percent since the start of 2017, with notable strength coming after the company released impressive data results at the American Society of Hematology conference. The Analyst Maxim Group's Jason McCarthy downgraded bluebird...
-
Maxim Explains Why Gilead Sciences Is A Now A Buy
Thursday, November 30, 2017 - 2:58pm | 474Gilead Sciences, Inc. (NASDAQ: GILD) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday. The Analyst Maxim Group analyst Jason McCarthy upgraded his rating on the shares of Gilead Sciences from Hold to Buy and set a $94 price...
-
OncoSec Shares Spike 17% After New Data Defended
Thursday, October 19, 2017 - 2:38pm | 824OncoSec Medical Inc (NASDAQ: ONCS) shares spiked about 20 percent intraday Thursday amid the release of positive mid-stage trial data for its investigational therapy ImmuoPulse IL-12 as a monotherapy and in combination with Pembrolizumab (Keytruda) for treating predicted anti-PD-1 non-responder...
-
Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating
Thursday, September 29, 2016 - 11:53am | 318With the only drug candidate that was close to approval for sickle cell now off the table, Maxim’s Jason McCarthy believes that bluebird bio Inc (NASDAQ: BLUE) could see a larger opportunity for its gene therapy, LentiGlobin. McCarthy maintained a Buy rating on the company, while raising...
-
Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim
Saturday, March 12, 2016 - 1:04pm | 408Shares of Agenus Inc (NASDAQ: AGEN) were trading up more than 9 percent on Friday afternoon, after Maxim Group upgraded its rating on the stock from Hold to Buy, while establishing a price target of $7.00. Analysts Jason McCarthy and Jason Kolbert highlighted a few elements behind their...